Division of Hematology/Oncology, Children's Hospital Los Angeles, Los Angeles, California, USA.
Int J Radiat Oncol Biol Phys. 2013 Aug 1;86(5):942-8. doi: 10.1016/j.ijrobp.2013.04.037. Epub 2013 May 29.
To identify the incidence and the risk factors for pulmonary toxicity in children treated for cancer with contemporary lung irradiation.
We analyzed clinical features, radiographic findings, pulmonary function tests, and dosimetric parameters of children receiving irradiation to the lung fields over a 10-year period.
We identified 109 patients (75 male patients). The median age at irradiation was 13.8 years (range, 0.04-20.9 years). The median follow-up period was 3.4 years. The median prescribed radiation dose was 21 Gy (range, 0.4-64.8 Gy). Pulmonary toxic chemotherapy included bleomycin in 58.7% of patients and cyclophosphamide in 83.5%. The following pulmonary outcomes were identified and the 5-year cumulative incidence after irradiation was determined: pneumonitis, 6%; chronic cough, 10%; pneumonia, 35%; dyspnea, 11%; supplemental oxygen requirement, 2%; radiographic interstitial lung disease, 40%; and chest wall deformity, 12%. One patient died of progressive respiratory failure. Post-irradiation pulmonary function tests available from 44 patients showed evidence of obstructive lung disease (25%), restrictive disease (11%), hyperinflation (32%), and abnormal diffusion capacity (12%). Thoracic surgery, bleomycin, age, mean lung irradiation dose (MLD), maximum lung dose, prescribed dose, and dosimetric parameters between V22 (volume of lung exposed to a radiation dose ≥22 Gy) and V30 (volume of lung exposed to a radiation dose ≥30 Gy) were significant for the development of adverse pulmonary outcomes on univariate analysis. MLD, maximum lung dose, and Vdose (percentage of volume of lung receiving the threshold dose or greater) were highly correlated. On multivariate analysis, MLD was the sole significant predictor of adverse pulmonary outcome (P=.01).
Significant pulmonary dysfunction occurs in children receiving lung irradiation by contemporary techniques. MLD rather than prescribed dose should be used to perform risk stratification of patients receiving lung irradiation.
确定采用现代肺部放射治疗的癌症患儿发生肺部毒性的发生率和危险因素。
我们分析了 10 年来接受肺部照射的患儿的临床特征、影像学表现、肺功能检查和剂量学参数。
我们共确定了 109 例患者(75 例男性)。照射时的中位年龄为 13.8 岁(范围,0.04-20.9 岁)。中位随访时间为 3.4 年。中位处方剂量为 21 Gy(范围,0.4-64.8 Gy)。肺部毒性化疗包括博来霉素(58.7%的患者)和环磷酰胺(83.5%的患者)。我们确定了以下肺部结果,并确定照射后的 5 年累积发生率:肺炎,6%;慢性咳嗽,10%;肺炎,35%;呼吸困难,11%;需要补充氧气,2%;间质性肺病,40%;胸廓畸形,12%。1 例患者死于进行性呼吸衰竭。从 44 例患者中获得的照射后肺功能检查显示存在阻塞性肺病(25%)、限制性疾病(11%)、过度充气(32%)和异常弥散能力(12%)。单变量分析显示,胸部放疗、博来霉素、年龄、平均肺照射剂量(MLD)、最大肺剂量、处方剂量和 V22(暴露于 22 Gy 及以上剂量的肺体积)与 V30(暴露于 30 Gy 及以上剂量的肺体积)之间的剂量学参数与不良肺部结局的发生相关。MLD、最大肺剂量和 Vdose(接受阈值剂量或更大剂量的肺体积百分比)高度相关。多变量分析显示,MLD 是不良肺部结局的唯一显著预测因素(P=.01)。
采用现代技术进行肺部放射治疗的患儿会出现明显的肺功能障碍。应使用 MLD 而不是处方剂量来对接受肺部照射的患者进行风险分层。